Breast Cancer Research and Treatment最新文献

{"title":"Breast imaging recommendations for young females (age < 40 years) with ≥ 20% lifetime breast cancer risk: practice patterns at a specialized clinic.","authors":"Alexandra Wehbe, Fisher Katlin, Eshita Sharma, Marybeth Hans, Mary Knust Graichen, Brittany L Bychkovsky, Rochelle Scheib, Judy E Garber, Lydia E Pace, Tari A King, Alison Laws","doi":"10.1007/s10549-025-07738-y","DOIUrl":"10.1007/s10549-025-07738-y","url":null,"abstract":"<p><strong>Purpose: </strong>The National Comprehensive Cancer Network (NCCN) and American Cancer Society (ACS) endorse differing guidelines for screening breast imaging among young females with familial breast cancer risk not driven by a germline pathogenic variant (PV). We sought to characterize practice patterns in our high-risk breast clinic related to screening breast imaging in this population.</p><p><strong>Methods: </strong>We identified all females aged 25-39 years with a first- or second-degree relative (FDR/SDR) with breast cancer and estimated lifetime breast cancer risk of ≥ 20% by the Tyrer-Cuzick (TC) version 7 model. Those with known PV in a breast cancer gene were excluded. We described provider recommendations for age to initiate screening and use of supplemental imaging modalities.</p><p><strong>Results: </strong>Among 334 included patients, 218 (65.3%) had an FDR with breast cancer and 116 (34.7%) had SDRs only. Screening prior to age 40 was recommended to 233 (69.8%) patients and varied by extent of family history and age of the youngest affected relative. Only a minority (24.1-27.0%) of recommendations aligned with NCCN or ACS guidelines. For the remaining patients, 82.2% and 48.7% were recommended to initiate screening younger than the NCCN or ACS guideline, respectively. Supplemental imaging with MRI or whole breast ultrasound was offered to 219 (65.6%) patients.</p><p><strong>Conclusion: </strong>Even in a specialized clinic, there is substantial variation in breast imaging recommendations for young females with elevated breast cancer risk based on family history. As formal risk assessment is increasingly adopted in clinical practice, this population should be a priority for future screening imaging studies.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"467-474"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Area deprivation index and breast cancer outcomes among patients in Western New York.","authors":"Malak Alharbi, Jayasree Krishnan, Arya Mariam Roy, Archit Patel, Ankita Kapoor, Riya Patel, Kayla Catalfamo, Kristopher Attwood, Han Yu, Varsha Gupta, Sheheryar Kabraji, Kazuaki Takabe, Thaer Khoury, Ellis Levine, Angela Omilian, Elizabeth Bouchard, Song Yao, Shipra Gandhi","doi":"10.1007/s10549-025-07733-3","DOIUrl":"10.1007/s10549-025-07733-3","url":null,"abstract":"<p><strong>Background: </strong>Several studies have shown that residing in regions with high area deprivation index (ADI) is associated with worse outcomes. We evaluated associations between ADI and breast cancer (BC) outcomes among patients in Western New York (WNY), a region that includes multiple underserved areas.</p><p><strong>Methods: </strong>This retrospective, single-institution study analyzed data from 404 BC patients diagnosed between 2014 and 2018. Demographic and clinicopathological data were abstracted. Data were compared between high (≥ 60) and low (< 60) ADI groups, reflective of high and low levels of socioeconomic disadvantage, respectively. The primary objective was overall survival (OS) by ADI. Secondary objectives included assessment of recurrence free survival (RFS) or time to next treatment (TNT) by ADI and frequency of germline and somatic testing.</p><p><strong>Results: </strong>Over half of the patients (59%) resided in ADI ≥ 60. 77% of patients had stage I-III BC and 23% had de novo metastatic BC. Patients in ADI ≥ 60 had a lower 5-year OS rate (73%) than those in ADI < 60 (84%) (95%CI: 67.5-79.7, P = 0.05). In multivariable analysis, similar trend was observed but was not statistically significant (HR 1.56, 95%CI: 0.98-2.46, P = 0.058). There were no differences in TNT or RFS by ADI. Germline testing was performed less frequently (33%) in ADI ≥ 60 than ADI < 60 group (45%) (P = 0.04) for patients with stage I-III BC, while no difference observed for stage IV patients. Finally, prevalence of somatic mutations in TP53, PIK3CA, and ESR1 were higher in ADI ≥ 60.</p><p><strong>Conclusions: </strong>We observed a trend towards worse OS in areas with high ADI, though not statistically significant. The incidence of germline testing was lower in high ADI compared to low ADI regions.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"21-31"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: a systematic review and meta-analysis.","authors":"Vitor Teixeira Liutti, David Laios do Vale, Bruno Lins de Souza, Rafael Ricci Ferrari Manea, Daniel Vilarim Araújo","doi":"10.1007/s10549-025-07746-y","DOIUrl":"10.1007/s10549-025-07746-y","url":null,"abstract":"<p><strong>Purpose: </strong>Pembrolizumab in combination with chemotherapy has become the standard neoadjuvant regimen for triple-negative breast cancer (TNBC). However, the KEYNOTE-522 trial did not use dose-dense (dd) anthracycline and cyclophosphamide (AC) as part of its chemotherapy backbone. This meta-analysis assesses the efficacy and safety of neoadjuvant ddAC in combination with carboplatin and paclitaxel (CT) and pembrolizumab.</p><p><strong>Methods: </strong>A systematic search was conducted to identify studies evaluating neoadjuvant ddAC in combination with CT and pembrolizumab, with or without comparisons to 3-weekly AC in TNBC. Statistical analysis was performed using random-effects model for studies comparing two schedules, and single-arm proportional meta-analysis to summarize endpoints for dose-dense regimen.</p><p><strong>Results: </strong>Four observational studies, comprising 535 patients (329 receiving ddAC and 206 receiving 3-weekly AC), met the inclusion criteria. Three studies compared the two schedules, while one evaluated ddAC. No difference in pCR was observed between both schedules (66.1% vs. 61.6%; RR 1.10; 95% CI 0.94-1.28; p = 0.25). However, patients receiving ddAC experienced higher incidence of grade III-IV adverse events (43.7% vs. 29.7%; RR 1.65; 95% CI 1.15-2.37; p = 0.007). No differences were found in dose modifications or treatment delays between the two schedules. In the combined analysis of studies evaluating ddAC, the overall pCR was 63%, with a 40% incidence of treatment delays. No included studies reported survival data for ddAC patients.</p><p><strong>Conclusion: </strong>Neoadjuvant pembrolizumab with ddAC demonstrated a pCR incidence comparable to that reported in the KEYNOTE-522 trial. When compared to 3-weekly AC, ddAC was associated with a higher toxicity, with no difference in pCR.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"427-434"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of indocyanine green and technetium-99 for dual-tracer sentinel lymph node biopsy in breast cancer.","authors":"Madison Kolbow, Qianyun Luo, Alicia Cerrato Grande, Schelomo Marmor, Jennifer Witt, Sydne Muratore, Todd M Tuttle, Jane Y C Hui","doi":"10.1007/s10549-025-07767-7","DOIUrl":"10.1007/s10549-025-07767-7","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to determine if indocyanine green (ICG) is a suitable replacement for blue dye for dual-tracer sentinel lymph node biopsy (SLNB).</p><p><strong>Methods: </strong>A single-center retrospective review of female breast cancer patients aged ≥ 18 years who underwent SLNB with technetium-99 (Tc⁹⁹) and ICG was performed from November 2022 to April 2024. Operative reports were reviewed to determine sentinel lymph node (SLN) identification rates with ICG (fluorescent) and Tc⁹⁹ (radioactive). Pathology reports were reviewed to determine the pathology of excised SLNs.</p><p><strong>Results: </strong>One hundred and nineteen SLNBs were performed on 117 patients. At least one radioactive or fluorescent SLN was identified in 93.2% of all patients. The mean number of SLNs retrieved per SLNB was 1.6 (fluorescent, 1.5; radioactive, 1.5). Of all excised SLNs, 89.4% were fluorescent, 88.4% were radioactive, and 81.9% were both fluorescent and radioactive. SLN metastases were present in 26 patients (22.2%); of SLNs identified with metastases on pathologic examination, 87.2% were fluorescent, 74.4% were radioactive, and 71.8% were both radioactive and fluorescent. Two patients (1.7%) experienced skin flap necrosis and one patient (0.9%) experienced prolonged skin discoloration. No patients experienced allergic reactions.</p><p><strong>Conclusion: </strong>This study demonstrates that SLN identification rates using ICG and Tc⁹⁹ are comparable to those using blue dye and Tc⁹⁹. Thus, ICG is a suitable alternative for blue dye. Future work should assess if ICG is a suitable tracer for SLNB in low-resource settings where Tc⁹⁹ is not available.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"151-159"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144504848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single bout of resistance or high-intensity interval training increases anti-cancer myokines and suppresses cancer cell growth in vitro in survivors of breast cancer.","authors":"Francesco Bettariga, Dennis R Taaffe, Cristina Crespo-Garcia, Timothy D Clay, Mauro De Santi, Giulia Baldelli, Sanjeev Adhikari, Elin S Gray, Daniel A Galvão, Robert U Newton","doi":"10.1007/s10549-025-07772-w","DOIUrl":"10.1007/s10549-025-07772-w","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is the leading cause of cancer-related death in women, highlighting the need for strategies to mitigate recurrence and mortality. We examined the effects of a single bout of resistance training (RT) versus high-intensity interval training (HIIT) on anti-cancer myokines and in vitro cancer cell suppression.</p><p><strong>Methods: </strong>Thirty-two survivors of breast cancer were randomly allocated to a single bout of RT (n = 16) or HIIT (n = 16). Blood was collected before, immediately post (0P) and 30 min post (30P) exercise. We measured serum levels of decorin, interleukin 6 (IL-6), secreted protein acidic and rich in cysteine (SPARC), and oncostatin M (OSM) and cell growth of MDA-MB-231 cells in vitro using real time cellular analysis at each time point.</p><p><strong>Results: </strong>Decorin, IL-6, and SPARC significantly increased (9 to 47%, p < 0.05) from baseline to 0P in both groups. IL-6 remained elevated in both groups at 30 min post-intervention (30P), while OSM levels were elevated only in the RT group at 30P. Between groups, IL-6 was significantly increased in HIIT at 0P (p = 0.001). Cancer cell growth was significantly reduced at 0P and 30P compared to baseline in RT (20 to 21%, p < 0.05) and HIIT (19 to 29%, p < 0.05), with significantly greater effects on MDA-MB-231 cell growth reduction in favour of HIIT at 0P (p = 0.001).</p><p><strong>Conclusion: </strong>A single bout of RT or HIIT can increase levels of anti-cancer myokines and reduce the growth of MDA-MB-231 cells in vitro in survivors of breast cancer, potentially contributing to a lower risk of recurrence. This highlights the importance of exercise as a treatment with promising anti-cancer effects.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"171-180"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials.","authors":"Nour Maher Mustafa, Mus'ab Theeb Mustafa, Aws Khalid Abushanab, Hamza Muneer Alakhras, Anas Saed Abed, Sereen Ahmad Bani-Said, Laith Sami Othman, Areen Shdaifat","doi":"10.1007/s10549-025-07737-z","DOIUrl":"10.1007/s10549-025-07737-z","url":null,"abstract":"<p><strong>Background: </strong>Hormone receptor-positive (HR+) breast cancer continues to be a significant global challenge, as resistance to endocrine therapy (ET) often reduces its effectiveness. Entinostat (ENT), a novel and selective histone deacetylase inhibitor (HDACi), has been suggested to overcome the resistance. However, there is still ongoing debate regarding its efficacy and safety.</p><p><strong>Objective: </strong>Our meta-analysis aims to assess the efficacy and safety of ENT plus exemestane (EXE) versus placebo (PL) plus EXE in patients with HR+ breast cancer.</p><p><strong>Methods: </strong>Following PRISMA guidelines, a systematic search was conducted across PubMed, Web of Science, and Cochrane Library up to November 2024, resulting in the inclusion of four randomized controlled trials (RCTs) involving 1371 patients. The primary outcomes were progression-free survival (PFS) and overall survival (OS), while secondary outcomes were the objective response rate (ORR), clinical benefit rate (CBR), and adverse events (AEs). Our meta-analysis was prospectively registered in PROSPERO (registration number: CRD42024615056).</p><p><strong>Results: </strong>Our Analysis showed that ENT + EXE significantly enhanced PFS in the overall HR+ population Hazard Ratio (HR) = 0.79 (95% CI 0.68-0.92; P = 0.003), particularly among human epidermal growth factor receptor-2 (HER2-) negative patients (HR = 0.80; 95% CI 0.68-0.95; P = 0.01) when compared to PL + EXE. However, no significant improvements were noted in OS (HR = 0.91; 95% CI 0.63-1.30; P = 0.60), ORR with relative risk (RR) = 1.37 (95% CI 0.90-2.07; P = 0.14), CBR (RR = 1.15; 95% CI 0.89-1.74; P = 0.29). Furthermore, our safety analysis demonstrated that patients receiving ENT + EXE experienced significantly higher rates of adverse events (AEs) of all grades, with a RR of 1.33 (95% CI 0.99-1.78) and a significant increase in grade ≥ 3 AEs (RR = 3.04; 95% CI 2.52-3.67).</p><p><strong>Conclusion: </strong>The ENT + EXE combination demonstrates significant PFS benefits in HR + breast cancer patients compared to PL + EXE. However, no improvements were seen in OS, ORR, or CBR. In addition, the higher incidence of AEs, especially hematologic and gastrointestinal, highlights the need for careful patient selection and monitoring.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"417-426"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to breast screening guidelines and breast cancer mortality: a population cohort study.","authors":"Rebecca A G Christensen, Geoffrey M Anderson, Shana J Kim, Arian Aminoleslami, Jennifer D Brooks","doi":"10.1007/s10549-025-07754-y","DOIUrl":"10.1007/s10549-025-07754-y","url":null,"abstract":"<p><strong>Background: </strong>Population-based breast screening programs diagnose cancers at earlier stage when they are easier to treat. Indeed, individuals screened as part of the Ontario Breast Screening Program (OBSP) are diagnosed with a lower stage of breast cancer than those who have never been screened. We sought to determine if adherence to OBSP guidelines is associated with differences in the rate of death from breast cancer in addition to cancer stage at diagnosis.</p><p><strong>Methods: </strong>48,927 women ≥ 51 years diagnosed with a first primary breast cancer in Ontario 2010-2017 were included and classified as an adherent screener, partial screener, or non-screener. The cohort was developed using administrative health databases linked by Ontario Health. Cause-specific hazard ratios (HR) and 95% confidence intervals (CI) were used to examine the association between adherence to OBSP guidelines and the rate of breast cancer death adjusting for age, rurality, and history of a prior cancer diagnosis. Death from non-breast cancer causes was considered a competing risk.</p><p><strong>Results: </strong>Compared to adherent screenings, non-screeners and non-adherent screeners had higher rates of death from breast cancer (HR: 3.59, 95% CI 3.30-3.90 and HR: 1.69, 95% CI 1.47-1.95 respectively). Further, non-adherent screeners (i.e., screened ≥ once) had a lower rate of breast cancer death than non-screeners (HR: 0.47, 95% CI 0.41-0.54).</p><p><strong>Interpretation: </strong>Individuals screened in the OBSP have a lower rate of death from breast cancer than non-screeners, even if they are not meeting screening guidelines. These findings suggest women should be encouraged to participate in breast screening regardless of their frequency of use.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"63-69"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arsenic in drinking water and breast cancer: a case-control study from a high exposure area in Northern Chile.","authors":"Estela Blanco, Johanna Acevedo, Liliana Pérez, Marian Herrera, Viviana Durán, Teresa Barlaro, Rodrigo Meza, Juan Carlos Roa, Roxana Parra, Hugo Benitez, Molly E Schwalb, Craig Steinmaus, Catterina Ferreccio","doi":"10.1007/s10549-025-07765-9","DOIUrl":"10.1007/s10549-025-07765-9","url":null,"abstract":"<p><strong>Purpose: </strong>Exposure to arsenic in drinking water is a cause of lung, bladder, and skin cancer, however the relation between arsenic and breast cancer is unclear. Northern Chile had high levels of arsenic in drinking water (up to 900 µg/l) between 1950 and 1970, facilitating the study of outcomes with long latency. We conducted a breast cancer case-control study in Northern Chile (2014-2018) and analyzed 505 incident breast cancer cases and 409 population-based female controls with data collected on lifetime exposure to arsenic and potential confounders.</p><p><strong>Methods: </strong>We identified cases in collaboration with cancer committees, hospitals, and medical facilities in the study area. Controls were recruited from the Chile Voter Registry. Logistic regression was used to assess the relationship between arsenic exposure and breast cancer adjusting for education and age. We evaluated cumulative, lifetime average and highest single year exposure with tertiles and quartiles and population weighted controls based on age and region of residence.</p><p><strong>Results: </strong>Exposure levels were high in both cases and controls, with median (interquartile range) values of: 52 (15-84) and 42 (10-106) μg/L for average lifetime concentration, respectively. Adjusted odds ratios (OR) for tertile of cumulative exposure to arsenic concentrations in water (< 1.17, 1.17-5.16, and ≥ 5.17 mg) were 1.00, 0.85 [95% confidence interval (CI), 0.60-1.18], and 1.10 (0.79-1.55). Results were similar for lifetime average and single-highest year exposure metrics.</p><p><strong>Conclusion: </strong>We did not find evidence of increased odds of higher arsenic exposure among incident breast cancer cases compared to female population controls.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"127-135"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOD2 expression in patients with triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and prognosis.","authors":"Yoon Young Kim, GunHee Lee, Yeonjin Jeon, Gyungyub Gong, Kyunggon Kim, JiSun Kim, Byung-Kwan Jeong, Hee Jin Lee","doi":"10.1007/s10549-025-07775-7","DOIUrl":"10.1007/s10549-025-07775-7","url":null,"abstract":"<p><strong>Purpose: </strong>Superoxide dismutase 2 (SOD2), an antioxidant enzyme, plays a pivotal role in carcinogenesis and immune regulation. In this study, we investigated the expression and implications of superoxide dismutase (SOD2) in triple-negative breast cancer (TNBC), an aggressive subtype with varying immune profiles and clinical outcomes.</p><p><strong>Methods: </strong>Multiple TNBC cohorts were analyzed with various methodologies including immunohistochemistry (IHC), proteomics, and RNA expressions. Immunostaining of SOD2 with tissue microarrays from 229 surgical samples and 144 pre-neoadjuvant chemotherapy biopsy samples were performed. Four hundred three formalin-fixed and paraffin-embedded samples underwent deparaffinization for protein extraction and three hundred thirty-six samples remained after quality control. Ninety-one TNBC samples from The Cancer Genome Atlas data and five hundred thirty-four TNBC samples from public database were also analyzed.</p><p><strong>Results: </strong>We identified positive correlations between SOD2 expression and immune-related genes, as well as tumor-infiltrating lymphocytes (TILs) levels, while observing negative associations with fibrosis-related pathways. Immunohistochemical analysis further supported the positive correlation between SOD2 and immune response. Furthermore, elevated SOD2 expression predicted favorable survival outcomes in patients with TNBC. Notably, analysis of single-cell RNA-seq data revealed increased SOD2 expression in cancer-associated fibroblasts associated with higher TILs levels, enhanced inflammatory signaling, and reduced fibrogenesis.</p><p><strong>Conclusion: </strong>High SOD2 expression in TNBC is associated with improved outcomes and heightened immune responses, underscoring its potential as a modulator of the tumor microenvironment.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"181-192"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to recruitment in a pre-surgical trial for ductal carcinoma in situ: an exploratory qualitative study of at-risk women, survivors, and providers.","authors":"Elizabeth J Adams, Veronica Zheng, Robin Cooper, Samantha Warwar, Denisha Brown, Lauren Schulte, Danielle Kline, Swati A Kulkarni","doi":"10.1007/s10549-025-07742-2","DOIUrl":"10.1007/s10549-025-07742-2","url":null,"abstract":"<p><strong>Purpose: </strong>A qualitative focus group study was conducted to explore the perceived motivators and barriers to clinical trial participation from the perspective of women at risk for ductal carcinoma in situ (DCIS), women with a history of DCIS, and healthcare providers who care for patients with DCIS to improve recruitment to a prospective multicenter randomized prospective window of opportunity study of a tissue selective estrogen complex in postmenopausal women with DCIS.</p><p><strong>Methods: </strong>Qualitative thematic analysis was applied to six online focus groups. The perceived motivators and barriers to participation in DCIS presurgical trials were assessed across groups. Baseline knowledge of DCIS and attitudes toward postmenopausal hormone therapies were also evaluated. Analysis was completed in NVivo.</p><p><strong>Results: </strong>Potential DCIS pre-surgical trial participants were motivated by altruism, receiving better care, and increased monitoring by the healthcare team. Conversely, the potential for the study drug to cause harm, distrust in the medical field, and the non-life-threatening nature of DCIS were barriers to participation in pre-surgical trial. Healthcare providers felt that participants were motivated by financial incentives and receiving better care. Surgical delays, an ineffective intervention, and participant anxiety were seen as barriers to participation.</p><p><strong>Conclusion: </strong>There was overlap in the perceived motivators and barriers to participation in a pre-surgical trial among women with a history of DCIS and at-risk women. However, healthcare providers identified differing perceived patient motivators and barriers from these groups, indicating that a greater understanding among health care providers of patient motivators and barriers may facilitate recruitment to DCIS pre-surgical trials.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"33-42"},"PeriodicalIF":3.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}